Foretinib (GSK1363089): Multikinase Inhibitor for Cancer Research

Executive Summary: Foretinib (GSK1363089) is a small-molecule, ATP-competitive inhibitor targeting VEGFRs and HGFR/Met with IC50 values between 0.4–9.6 nmol/L under standard kinase assay conditions (Schwartz 2022). It suppresses tumor cell growth and migration in multiple cancer cell lines, including B16F10 melanoma, PC-3 prostate, A549 lung, and HT29 colon, with MET cellular inhibition IC50 values of 21–23 nmol/L. Foretinib is highly soluble in DMSO (≥31.65 mg/mL) but insoluble in water and ethanol. In vivo, oral dosing at 30 mg/kg reduces tumor burden in ovarian cancer xenograft models. The compound is for research use only and is distributed by APExBIO (product page).

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFRs and HGFR/Met regulate angiogenesis, cell proliferation, and metastatic signaling in cancer. Dysregulation of these pathways is a hallmark of solid tumors and is linked to enhanced tumor growth, invasion, and poor prognosis (Schwartz 2022). Multikinase inhibitors like Foretinib are designed to block several RTKs simultaneously, addressing tumor heterogeneity and adaptive resistance. By targeting VEGF receptor signaling and HGF/Met-driven cell motility, Foretinib supports advanced in vitro and in vivo cancer research workflows.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is an ATP-competitive inhibitor. It binds the ATP-binding pocket of several RTKs, including MET, RON, KDR (VEGFR2), Flt-1, Flt-4 (VEGFR3), KIT, Flt-3, PDGFR α/β, and Tie-2. The IC50 values for these kinases range from 0.4 to 9.6 nmol/L, determined by biochemical kinase assays at 25°C and pH 7.4 in buffer containing 1 mM ATP (Schwartz 2022). Cellular MET inhibition occurs at IC50 values of approximately 21–23 nmol/L in human tumor cell lines. Foretinib blocks HGF-induced cell motility and causes G2/M cell cycle arrest, leading to reduced proliferation and migration (PLX3397.com). This multi-target action provides broader efficacy against tumor progression and metastasis compared to single-target agents.

Evidence & Benchmarks

• Foretinib inhibits MET, RON, KDR (VEGFR2), Flt-1, Flt-4, KIT, Flt-3, PDGFR α/β, and Tie-2 with IC50s between 0.4–9.6 nmol/L in vitro kinase assays (Schwartz 2022).
• Cellular assays show MET inhibition at 21–23 nmol/L in B16F10, PC-3, A549, and HT29 cell lines (Schwartz 2022).
• Foretinib suppresses tumor cell proliferation, migration, and invasion in dose-dependent manners in validated migration and invasion assays (Schwartz 2022).
• In vivo, oral administration at 30 mg/kg reduces metastatic tumor nodules and tumor weight in ovarian cancer xenografts in mice (Schwartz 2022).
• Solubility is ≥31.65 mg/mL in DMSO at room temperature; compound is insoluble in water and ethanol (APExBIO).

For a more detailed mechanistic review, see this article, which focuses on translational aspects and experimental strategies. The current dossier expands upon in vitro benchmarks and offers solubility guidance.

Applications, Limits & Misconceptions

Foretinib enables the study of tumor cell proliferation, migration, and in vivo metastasis in preclinical cancer models. Its multi-target profile makes it suitable for modeling complex tumor microenvironments and resistance mechanisms. Foretinib is recommended for:

• Cell motility inhibition assays (e.g., wound healing, transwell migration).
• Tumor cell growth inhibition in monolayer and spheroid cultures.
• In vivo xenograft and metastasis models (e.g., ovarian cancer in mice).
• Pathway dissection involving VEGFR, MET, and related RTKs.

This article extends the protocol coverage found in Dimesna.com by integrating in vitro response profiling with solubility and storage best practices.

Common Pitfalls or Misconceptions

• Foretinib is not suitable for diagnostic or therapeutic use in humans; it is for research use only (APExBIO).
• Solubility limitations: Foretinib is insoluble in water and ethanol; use DMSO for stock preparations.
• Storage conditions are critical: Stock solutions must be stored at -20°C and used promptly to avoid degradation.
• Single-agent resistance can develop: Multikinase inhibitors like Foretinib may require combination approaches in complex models (Schwartz 2022).
• IC50 values may vary by cell type and assay conditions: Always validate under specific experimental setups.

For further context, this article focuses on advanced in vitro assay design, while the present article emphasizes compound handling and cross-model benchmarks.

Workflow Integration & Parameters

Foretinib (A2974) from APExBIO is provided as a lyophilized powder. For experimental use:

• Prepare stock solutions at ≥31.65 mg/mL in anhydrous DMSO.
• Store aliquots at -20°C; avoid repeated freeze-thaw cycles.
• Dilute stocks freshly in cell culture buffer immediately before use.
• Validate dosing in each model system, starting at nanomolar concentrations for in vitro assays.
• For in vivo studies, oral dosing at 30 mg/kg has demonstrated efficacy in reducing tumor growth in mouse xenografts.

For product specifications and detailed protocols, refer to the Foretinib (GSK1363089) product page.

Conclusion & Outlook

Foretinib (GSK1363089) is a validated, potent ATP-competitive inhibitor of VEGFR and HGFR/Met, supporting multi-parametric cancer research. Its robust inhibition profile, solubility in DMSO, and proven in vivo efficacy in reducing tumor and metastatic burden make it a versatile tool for oncology workflows. With precise storage and handling, Foretinib enables reproducible modeling of tumor progression and resistance. For a broader discussion of next-generation multikinase inhibitors, see this guide, which adds perspective on experimental optimization beyond the scope of the present dossier.